Lung Cancer News

More than one in four adults and nearly one in 10 young adults in the United States report some form of tobacco use.

Two phase 3 studies designed to evaluate veliparib in combination with chemotherapy failed to meet their primary endpoints, according to the drug’s manufacturer.

A telephone-based counseling intervention following lung cancer screening increased cessation rates among current smokers, according to study results published in Lung Cancer.

First-line treatment with alectinib extended PFS compared with crizotinib among patients with anaplastic lymphoma kinase–positive advanced non–small cell lung cancer, according to results of a phase 3 trial.

Approximately one in five patients with the most common form of lung cancer did not receive cancer-specific treatment, according to study results published in Journal of Thoracic Oncology.

Nivolumab led to a 5-year survival rate much higher than historical rates in patients with advanced non–small cell lung cancer, according to long-term survival data presented at the American Association for Cancer Research Annual Meeting.

A phase 3 study designed to evaluate alectinib in patients with anaplastic lymphoma kinase–positive advanced non–small cell lung cancer met its primary endpoint of improved PFS, according to the drug’s manufacturer.

The FDA granted regular approval to osimertinib for the treatment of certain patients with metastatic non–small cell lung cancer.

Black and American Indian patients with stage I non–small cell lung cancer had higher rates of overall and cancer-specific mortality than white patients, a disparity that has persisted over time, according to results of a SEER analysis presented at the Multidisciplinary Thoracic Cancers Symposium.

Blood tests that used circulating tumor cells as biomarkers detected recurrences of locally advanced non–small cell lung cancer months earlier than conventional CT imaging methods, according to a prospective clinical trial presented at the Multidisciplinary Thoracic Cancers Symposium.